Max-40279-01
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for Max-40279-01, covering 2021-10-01 to 2022-06-02. Get the full timeline:
Most recent: Clinical Trial Update: A Phase 2 Study to Evaluate the Safety and Efficacy of Max-40279-01 in Patients With Advanced Gastric Cancer or Gastroesophageal Junction Cancer [Phase 2]